BRD7

Across TCGA pan-cancer cohorts, BRD7 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated BRD7 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher BRD7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BRD7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

COAD, PDAC, and GBM are the cancer types where BRD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Quartile	All	0.871	1.000	.012	60	view →
PDAC	DFS	Median	All	0.913	0.679	<.001	32	view →
GBM	DFS	Tertile	All	0.474	0.284	.008	7	view →
LSCC	DFS	Median	All	0.973	0.902	.004	6	view →
HNSC	OS	Median	All	1.000	0.959	.023	5	view →
OV	DFS	Quartile	All	0.533	1.000	.049	4	view →
LUAD	DFS	Quartile	II,III,IV	0.240	0.641	.012	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

BRD7–COAD (DFS)

Open the COAD breakdown →